Related Experiment Videos
Red cell alloantibodies produced after bone marrow transplantation
Transfusion
|March 1, 1987
Summary
Bone marrow transplants can lead to the development of red blood cell alloantibodies in patients. These antibodies, targeting various blood group antigens, can appear months after transplantation, posing potential risks.
Area of Science:
- Immunology
- Hematology
- Transplantation Medicine
Background:
- Bone marrow transplantation (BMT) is a critical treatment for various hematologic and oncologic conditions.
- Alloimmunization, the development of antibodies against foreign antigens, is a known complication in transfusion medicine and transplantation.
Purpose of the Study:
- To investigate the incidence and characteristics of red cell alloantibody production in patients following allogeneic bone marrow transplantation.
- To identify the specificities of newly formed red cell alloantibodies post-transplantation.
Main Methods:
- Retrospective analysis of 150 patients undergoing bone marrow transplantation.
- Monitoring for the development of red cell alloantibodies through serological testing.
- Characterization of antibody specificities using standard blood bank techniques.
Main Results:
- Red cell alloantibodies were detected in 13 out of 150 patients (8.7%) post-transplantation.
- Antibody formation occurred between 12 days and 11 months after BMT.
- Identified specificities included anti-N, -Jka, -E-like, -Kell-like, -M, -Leb, -Hl, -H, and -A1.
Conclusions:
- Post-transplantation alloantibody production is a significant concern in bone marrow transplant recipients.
- Potential mechanisms include transfused immunocompetent lymphocytes, the grafted immune system, or residual host immune cells.
- These findings highlight the importance of vigilant antibody screening in BMT patients.